Merck's Sac-TMT Trial for Advanced Ovarian Cancer Aims to Improve Maintenance Treatment Outcomes
Merck is conducting a clinical trial to evaluate sacituzumab tirumotecan (sac-TMT) as a maintenance treatment for advanced ovarian cancer.
Asset / Drug
Drug and asset intelligence for bevacizumab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.